BACKGROUND: Germline mutations in the BRCA1 and BRCA2 tumour-suppressor genes predispose to early-onset breast and ovarian cancer. Although both genes display a highly heterogeneous mutation spectrum, a number of alterations recur in some populations. Only a limited number of founder mutations have been identified in the Italian population so far. OBJECTIVE: To investigate the spectrum of BRCA1/BRCA2 mutations in a set of families originary from the Central-Eastern part of Tuscany and to ascertain the presence of founder effects. We also wanted to approximate the age of the most frequent BRCA1 founder mutation. RESULTS: Overall, four distinct BRCA1 mutations accounted for a large fraction (72.7%) of BRCA1-attributable hereditary breast/ovarian cancer in families originary from this area. We identified common haplotypes for two newly recognised recurrent BRCA1 mutations, c.3228_3229delAG and c.3285delA. The c.3228_3229delAG mutation was estimated to have originated about 129 generations ago. Interestingly, male breast cancer cases were present in 3 out of 11 families with the c.3228_3229delAG mutation. CONCLUSIONS: The observation that a high proportion of families with BRCA1 alterations from Central-Eastern Tuscany harbours a limited number of founder mutations can have significant impact on clinical management of at risk subjects from this area. In addition, the identification of a large set of families carrying an identical mutation that predisposes to breast and ovarian cancer provides unique opportunities to study the effect of other genetic and environmental factors on penetrance and disease phenotype.
BACKGROUND: Germline mutations in the BRCA1 and BRCA2 tumour-suppressor genes predispose to early-onset breast and ovarian cancer. Although both genes display a highly heterogeneous mutation spectrum, a number of alterations recur in some populations. Only a limited number of founder mutations have been identified in the Italian population so far. OBJECTIVE: To investigate the spectrum of BRCA1/BRCA2 mutations in a set of families originary from the Central-Eastern part of Tuscany and to ascertain the presence of founder effects. We also wanted to approximate the age of the most frequent BRCA1 founder mutation. RESULTS: Overall, four distinct BRCA1 mutations accounted for a large fraction (72.7%) of BRCA1-attributable hereditary breast/ovarian cancer in families originary from this area. We identified common haplotypes for two newly recognised recurrent BRCA1 mutations, c.3228_3229delAG and c.3285delA. The c.3228_3229delAG mutation was estimated to have originated about 129 generations ago. Interestingly, male breast cancer cases were present in 3 out of 11 families with the c.3228_3229delAG mutation. CONCLUSIONS: The observation that a high proportion of families with BRCA1 alterations from Central-Eastern Tuscany harbours a limited number of founder mutations can have significant impact on clinical management of at risk subjects from this area. In addition, the identification of a large set of families carrying an identical mutation that predisposes to breast and ovarian cancer provides unique opportunities to study the effect of other genetic and environmental factors on penetrance and disease phenotype.
Authors: Laura Ottini; Carlo Capalbo; Piera Rizzolo; Valentina Silvestri; Giuseppe Bronte; Sergio Rizzo; Antonio Russo Journal: Breast Cancer (Dove Med Press) Date: 2010-10-04
Authors: Maria De Bonis; Angelo Minucci; Giovanni Luca Scaglione; Elisa De Paolis; Gianfranco Zannoni; Giovanni Scambia; Ettore Capoluongo Journal: Fam Cancer Date: 2019-01 Impact factor: 2.375
Authors: Giulia Cini; Massimo Mezzavilla; Lara Della Puppa; Elisa Cupelli; Alessio Fornasin; Angela Valentina D'Elia; Riccardo Dolcetti; Giuseppe Damante; Sara Bertok; Gianmaria Miolo; Roberta Maestro; Paolo de Paoli; Antonio Amoroso; Alessandra Viel Journal: BMC Med Genet Date: 2016-02-06 Impact factor: 2.103
Authors: Grazia Palomba; Angela Loi; Antonella Uras; Patrizia Fancello; Giovanna Piras; Attilio Gabbas; Antonio Cossu; Mario Budroni; Antonio Contu; Francesco Tanda; Antonio Farris; Sandra Orrù; Carlo Floris; Marina Pisano; Mario Lovicu; Maria Cristina Santona; Gennaro Landriscina; Laura Crisponi; Giuseppe Palmieri; Maria Monne Journal: BMC Cancer Date: 2009-07-20 Impact factor: 4.430
Authors: Laura Caleca; Anna Laura Putignano; Mara Colombo; Caterina Congregati; Mohosin Sarkar; Thomas J Magliery; Carla B Ripamonti; Claudia Foglia; Bernard Peissel; Daniela Zaffaroni; Siranoush Manoukian; Carlo Tondini; Monica Barile; Valeria Pensotti; Loris Bernard; Laura Papi; Paolo Radice Journal: PLoS One Date: 2014-02-06 Impact factor: 3.240